Vanderbilt Eye Institute (VEI) investigators have inched nearer towards decoding a principal reason for sightlessness in the U.S. – glaucoma.
During the course of a latest study, David Calkins, Ph.D, helming Research area, VEI, uncovered that the preliminary symptoms of glaucoma injury essentially takes place in the brain.
Glaucoma is usually deemed condition of the eye wherein sensitiveness to ocular pressure leads to retinal and optic nerve harm, that are constituents of the CNS (central nervous system) and do not rejuvenate. The inception of harm is in the peripheral ocular field and progressing steadily towards the core leading to total sightlessness until diagnosed early on. Due to this reason, deterioration in glaucoma is mostly tricky to identify.
The outcomes of the latest trials conducted wherein Calkins’ lab illustrated how glaucoma bears major resemblance to other CNS conditions.
The investigators are hopeful that this discovery would lead to a hypothesis budge on what is normally thought about this condition and would have worldwide insinuations.
Merging this new-fangled perception about the location of foremost neuronal glaucoma harm happening with the information that the frequency of harm rises in proportion to age, investigators have presently been able to gain insight as to the manner in which sensory function failure takes place in typical aging.
Conventionally, glaucoma treatments have laid emphasis on reducing ocular pressure inside the eye. However, the latest PNAS trial has given credibility to take a novel course of trial that focuses on neuronal activity in the centre of the brain where the optic nerve has been known to form its foremost links.
This enthralling work illustrates that the brain must also be considered along with the eye, in an endeavour at understanding blindness-causing conditions like glaucoma.
Calkins explicated that in other age-associated disorders such as Parkinson’s disease and Alzheimer’s disease, the significant contributory factor to neuronal sensitivity to injury is aging.
In such conditions, harm to the neurons happens quite early via a course known as dying back occurring in the distal projections. During the dying back process, the neuronal axon’s communication capability with the target is lost.
In glaucoma, it has been shown that the axons present in the optic nerve become incapable of communicating with their targeted location in the middle area of the brain.
Calkin’s research group were anticipating to locate a communication loss in the eye’s optic nerve, however found that the communication in between brain and optic nerve would die firstly.
When employed on animal models having high pressure glaucoma, the group found that preliminary eyesight failure involved lost communication in-between the optic nerve and central part of the brain where sensory data regarding sounds, pains, heat, pressure and cold is noted to originate.
The researchers explicated that when on closely following the condition, in eventual course of time, the optic nerve and afterwards the retina showed deterioration signs. Hence, the deterioration occurs reversely from the brain and then working itself back to the retina, thus the final staging of the condition, the initial structures, those closest to the eye were the last ones to go.
Presently, the group is endeavouring to find medications which could enhance or reinstate the connection in-between middle part of the brain and optic nerve. Employing man-made compounds and innate nerve growth factors like BDNF (Brain-Derived Neurotropic Factor), the group is evaluating ways of restoring connectivity in the path.
The trial additionally initiates the likelihood of employing MRI scanning procedure as a preliminary diagnostic device for spotting early symptoms of glaucoma injury in the brain.
